Terms: = Colorectal cancer AND MAPK1, MAPK2, 5594, ENSG00000100030, P28482, ERK2, p40, PRKM1, p38, p41, ERT1, p41mapk, PRKM2, P42MAPK, ERK AND Clinical Outcome
16 results:
1. colorectal adenosquamous carcinoma: Peculiar morphologic features and distinct immunoprofiles in squamous and glandular components.
Parente P; Mastracci L; Vanoli A; Businello G; Paudice M; Angerilli V; Castelvetere M; Graziano P; Fassan M; Grillo F
Pathol Res Pract; 2022 Aug; 236():153967. PubMed ID: 35662040
[TBL] [Abstract] [Full Text] [Related]
2. AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status.
Ma R; Xu L; Qu X; Che X; Zhang Y; Fan Y; Li C; Guo T; Hou K; Hu X; Drew L; Shen M; Cheung T; Liu Y
Br J Cancer; 2018 May; 118(11):1453-1463. PubMed ID: 29755114
[TBL] [Abstract] [Full Text] [Related]
3. Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in
Hazar-Rethinam M; Kleyman M; Han GC; Liu D; Ahronian LG; Shahzade HA; Chen L; Parikh AR; Allen JN; Clark JW; Kwak EL; Faris JE; Murphy JE; Hong TS; Van Seventer EE; Nadres B; Hong CB; Gurski JM; Jessop NA; Dias-Santagata D; Iafrate AJ; Van Allen EM; Corcoran RB
Cancer Discov; 2018 Apr; 8(4):417-427. PubMed ID: 29431697
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic significance of USP33 in advanced colorectal cancer patients: new insights into β-arrestin-dependent erk signaling.
Liu H; Zhang Q; Li K; Gong Z; Liu Z; Xu Y; Swaney MH; Xiao K; Chen Y
Oncotarget; 2016 Dec; 7(49):81223-81240. PubMed ID: 27835898
[TBL] [Abstract] [Full Text] [Related]
5. Cytotoxicity of PEGylated liposomes co-loaded with novel pro-apoptotic drug NCL-240 and the MEK inhibitor cobimetinib against colon carcinoma in vitro.
Sriraman SK; Geraldo V; Luther E; Degterev A; Torchilin V
J Control Release; 2015 Dec; 220(Pt A):160-168. PubMed ID: 26497930
[TBL] [Abstract] [Full Text] [Related]
6. Protein phosphatase methylesterase-1 (PME-1) expression predicts a favorable clinical outcome in colorectal cancer.
Kaur A; Elzagheid A; Birkman EM; Avoranta T; Kytölä V; Korkeila E; Syrjänen K; Westermarck J; Sundström J
Cancer Med; 2015 Dec; 4(12):1798-808. PubMed ID: 26377365
[TBL] [Abstract] [Full Text] [Related]
7. Co-existence of BRAF V600E Gene Mutation in Tumor and Non-tumoral Surrounding Tissues in colorectal cancer.
Öztürk T; Toptaş-Hekimoğlu B; Eronat AP; Saygili N; Dağlar-Aday A; Başsüllü N; Türkmen I; Aydoğan HY; Bülbül G; Göksel S; Öztürk O; Isbir T
In Vivo; 2015; 29(5):577-84. PubMed ID: 26359417
[TBL] [Abstract] [Full Text] [Related]
8. ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs).
Prasetyanti PR; Capone E; Barcaroli D; D'Agostino D; Volpe S; Benfante A; van Hooff S; Iacobelli V; Rossi C; Iacobelli S; Medema JP; De Laurenzi V; Sala G
Oncotarget; 2015 Jul; 6(19):16902-11. PubMed ID: 26160848
[TBL] [Abstract] [Full Text] [Related]
9. RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth.
Depeille P; Henricks LM; van de Ven RA; Lemmens E; Wang CY; Matli M; Werb Z; Haigis KM; Donner D; Warren R; Roose JP
Nat Cell Biol; 2015 Jun; 17(6):804-15. PubMed ID: 26005835
[TBL] [Abstract] [Full Text] [Related]
10. Implication of metastasis suppressor gene, Kiss-1 and its receptor Kiss-1R in colorectal cancer.
Ji K; Ye L; Ruge F; Hargest R; Mason MD; Jiang WG
BMC Cancer; 2014 Sep; 14():723. PubMed ID: 25260785
[TBL] [Abstract] [Full Text] [Related]
11. TRAP1 is involved in BRAF regulation and downstream attenuation of erk phosphorylation and cell-cycle progression: a novel target for BRAF-mutated colorectal tumors.
Condelli V; Piscazzi A; Sisinni L; Matassa DS; Maddalena F; Lettini G; Simeon V; Palladino G; Amoroso MR; Trino S; Esposito F; Landriscina M
Cancer Res; 2014 Nov; 74(22):6693-704. PubMed ID: 25239454
[TBL] [Abstract] [Full Text] [Related]
12. Is biomarker research advancing in the era of personalized medicine for head and neck cancer?
Yokota T
Int J Clin Oncol; 2014 Apr; 19(2):211-9. PubMed ID: 24442754
[TBL] [Abstract] [Full Text] [Related]
13. Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression.
Wang Y; Velho S; Vakiani E; Peng S; Bass AJ; Chu GC; Gierut J; Bugni JM; Der CJ; Philips M; Solit DB; Haigis KM
Cancer Discov; 2013 Mar; 3(3):294-307. PubMed ID: 23274911
[TBL] [Abstract] [Full Text] [Related]
14. VEGFA gene locus (6p12) amplification identifies a small but highly aggressive subgroup of colorectal cancer [corrected] patients.
Vlajnic T; Andreozzi MC; Schneider S; Tornillo L; Karamitopoulou E; Lugli A; Ruiz C; Zlobec I; Terracciano L
Mod Pathol; 2011 Oct; 24(10):1404-12. PubMed ID: 21743435
[TBL] [Abstract] [Full Text] [Related]
15. erk signaling in colorectal cancer: a preliminary report on the expression of phosphorylated erk and the effects of radiation therapy.
Corn BW; Kovner F; Bek S; Wexler I; Lifschits B; Seger R
Am J Clin Oncol; 2008 Jun; 31(3):255-8. PubMed ID: 18525304
[TBL] [Abstract] [Full Text] [Related]
16. n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced erk-1 and -2 and HIF-1alpha induction pathway.
Calviello G; Di Nicuolo F; Gragnoli S; Piccioni E; Serini S; Maggiano N; Tringali G; Navarra P; Ranelletti FO; Palozza P
Carcinogenesis; 2004 Dec; 25(12):2303-10. PubMed ID: 15358633
[TBL] [Abstract] [Full Text] [Related]
